U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry UNKNOWN
Molecular Formula C15H16N4O2
Molecular Weight 284.3131
Optical Activity ( - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NICARAVEN, (-)-

SMILES

CC(CNC(=O)C1=CC=CN=C1)NC(=O)C2=CC=CN=C2

InChI

InChIKey=KTXBOOWDLPUROC-UHFFFAOYSA-N
InChI=1S/C15H16N4O2/c1-11(19-15(21)13-5-3-7-17-10-13)8-18-14(20)12-4-2-6-16-9-12/h2-7,9-11H,8H2,1H3,(H,18,20)(H,19,21)

HIDE SMILES / InChI

Molecular Formula C15H16N4O2
Molecular Weight 284.3131
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Nicaraven is a hydroxyl radical scavenger with antivasospastic and neuroprotective effects. Chugai (the Japanese subsidiary of Roche) is developing nicaraven (Antevas), a water-soluble antioxidant, for the potential treatment of disorders caused by acute cerebrovascular diseases. A registration application was filed in April 1995, and in April 2002, nicaraven was still awaiting registration in Japan. By August 2002, Chugai had filed an NDA in Japan for the additional indication of subarachnoidal bleeding.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.5 mM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Effects of a hydroxyl radical scavenger on delayed ischemic neurological deficits following aneurysmal subarachnoid hemorrhage: results of a multicenter, placebo-controlled double-blind trial.
1996 May
The potential benefits of nicaraven to protect against radiation-induced injury in hematopoietic stem/progenitor cells with relative low dose exposures.
2014 Sep 26
Nicaraven, a Potential Radioprotective Agent, has Very Limited Effects on the Survival of Cancer Cells and the Growth of Established Tumors.
2017 Feb 22
Patents

Patents

Sample Use Guides

4 g nicaraven infused intravenously for 6-8 hours once a day
Route of Administration: Intravenous
The antiplatelet activities in vitro of nicaraven were examined. The concentrations of nicaraven tested were 3.50 x 10(-5) mol/L, 1.75 x 10(-4) mol/L, 3.50 x 10(-4) mol/L, and 1.75 x 10(-3) mol/L, respectively. The maximum aggregation rate induced by adenosine diphosphate (ADP) was significantly inhibited by nicaraven at concentration ranges of 3.50 x 10(-4) mol/L or higher in the healthy volunteer platelets. The maximum aggregation rate induced by collagen was significantly inhibited by 1.75 x 10(-3) mol/L of nicaraven. Using platelets from patients with cerebral thrombosis, the maximum aggregation rate induced by ADP was significantly inhibited by 1.75 x 10(-3) mol/L of nicaraven. Furthermore, the maximum aggregation rate induced by collagen were significantly reduced by 1.75 x 10(-3) mol/L of nicaraven.
Substance Class Chemical
Created
by admin
on Sat Dec 16 11:04:46 GMT 2023
Edited
by admin
on Sat Dec 16 11:04:46 GMT 2023
Record UNII
K13EV3J70Q
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NICARAVEN, (-)-
Common Name English
3-PYRIDINECARBOXAMIDE, N,N'-(1-METHYL-1,2-ETHANEDIYL)BIS-, (-)-
Systematic Name English
Code System Code Type Description
PUBCHEM
71234
Created by admin on Sat Dec 16 11:04:46 GMT 2023 , Edited by admin on Sat Dec 16 11:04:46 GMT 2023
PRIMARY
FDA UNII
K13EV3J70Q
Created by admin on Sat Dec 16 11:04:46 GMT 2023 , Edited by admin on Sat Dec 16 11:04:46 GMT 2023
PRIMARY
Related Record Type Details
RACEMATE -> ENANTIOMER
ENANTIOMER -> ENANTIOMER